Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

NCT02221401 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Linagliptin/Metformin FDC
DRUG: Linagliptin
DRUG: Metformin

Sponsor

Boehringer Ingelheim